

**Genentech, Inc.**

1 DNA WAY  
South San Francisco, CA 94080  
(650) 225-1000  
Facsimile: (650) 952-9881

**FACSIMILE TRANSMITTAL**

**RECEIVED**  
**CENTRAL FAX CENTER**

SEP 15 2004

DATE: September 15, 2004

Please deliver the following page(s) to:

## NAME:


US Patent and Trademark Office

Fax No.: (703) 872-9306

FROM: David W Evans  
Registration No.: \*

RE: U.S. Serial No.: 10/618,178  
Our Docket No.: P1862R1C1

Number of Pages including this cover sheet -

<b>CERTIFICATION OF FACSIMILE TRANSMISSION</b>	
<b>UNDER 37 CFR § 1.8</b>	
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
<u>David W Evans</u>	
Type or print name of person signing certification	
Signature 	Date: <u>September 15, 2004</u>

**CONFIDENTIAL NOTE**

The documents accompanying this facsimile transmission contain information from GENENTECH, INC. which is confidential or privileged. The information is intended only for the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this faxed information is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us and the retransmission of them to the intended recipient.

If you do not receive all pages, please notify Aida Guiam at (650) 225-1732.


Re: USSN 10/618,178 Filed July 11, 2003

\* A copy of a document pursuant to 37 C.F.R. §10.9(b) is attached as proof of the authorization of the above to prosecute the attached application.  
The original of this document is on file in the Office of enrollment and Discipline.

SEP 15 2004

Patent Docket P1862R1C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Daniel J. Burdick et al.  Serial No.: 10/618,178  Filed: July 11, 2003  For: LFA-1 ANTAGONIST COMPOUNDS	Group Art Unit: 1614  Examiner: Aulakh, C  Confirmation No: 4372  Customer No: 09157  <small>CERTIFICATE OFFACSIMILE TRANSMISSION I hereby certify that this correspondence is being faxed with the United States Patent and Trademark Office addressed to: Commissioner for Patents on</small>  September 15, 2004   David W Evans
---	--

**AMENDMENT TRANSMITTAL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.


	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	21	-	2023	0	18	<del>\$18.00</del> 0
Independent	1	-	3		86	\$0.00
Multiple dependent claim(s), if any					290	\$0.00
Total Fee Calculation						<del>\$18.00</del> 0

- ☒ No additional fee is required.  
☐ The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$. A duplicate copy of this transmittal is enclosed.  
☒ Petition for Extension of Time is enclosed. A duplicate copy of this transmittal is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,  
GENENTECH, INC.

Date: September 15, 2004  
1 DNA Way  
So. San Francisco, CA 94080-4990

By:   
David W Evans  
Reg. No. \*  
Telephone No. (650) 225-1739


**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE  
UNITED STATES PATENT AND TRADEMARK OFFICE**

**LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)**

David Evans is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of Genentech, Inc. to prepare and prosecute patent applications in which Genentech, Inc. is the assignee of record of the entire interest. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) David Evans ceases to lawfully reside in the United States, (ii) David Evans' employment with Genentech, Inc. ceases or is terminated, or (iii) David Evans ceases to remain or reside in the United States on an H1B1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

**Expires: April 6, 2005**

  
\_\_\_\_\_  
Harry I. Moatz  
Director of Enrollment and Discipline